Table 2.
Examples of clinical trials using nanocarrier-based DDS in treatment of LC. *
| Type of NPs | Cargo/Therapy | Status | Patient/Ccondition | Stage | ClinicalTrials.gov Identifier: |
|---|---|---|---|---|---|
| Liposomes | Drug: LY01610 (Irinotecan hydrochloride liposome injection) | Recruiting | SCLC | Phase 2 | NCT04381910 |
| Liposomes | Device: Liposomal DOX combined with ifosfamide | Unknown | SCLC | Phase 2 | NCT01872416 |
| Liposomes | Drug: PLM60 | Recruiting | SCLC | Phase 2 | NCT04352413 |
| Liposomes | Drug: MRX34 | Terminated | SCLC | Phase 1 | NCT01829971 |
| Polymeric-PEG | Drug: ADI-PEG 20 (Arginine deiminase pegylated) | Terminated | SCLC | Phase 2 | NCT01266018 |
| Polymeric-PEG | Drug: LCL161 Drug: Topotecan Drug: Pegylated GCSF (PEG-GCSF) |
Terminated | LC | Phase 1, Phase 2 | NCT02649673 |
| Polymeric-PEG | Drug: Pegylated irinotecan | Completed | SCLC | Phase 2 | NCT01876446 |
| Polymeric-PEG | Drug: Pegylated irinotecan | Recurrent Small Cell | LC | Phase 2 | NCT01876446 |
| Polymeric-PEG | Drug: PEG-rhG-CSF | Unknown | SCLC | Not Applicable | NCT03776604 |
| Polymeric-PEG | Drug: ADI-PEG 20 | Completed | Solid tumors NSCLC |
Phase 1 | NCT01497925 |
| Polymeric-PEG | Drug: Pegylated recombinant human endostatin (PEG-ENDO) | Recruiting | Solid tumors NSCLC |
Phase 1 | NCT04413227 |
| Polymeric-PEG | Drug: PEG-rhG-CSF | Completed | Malignant Solid Tumor LC |
Phase 4 | NCT02805166 |
| Polymeric-PEG | Drug: YPEG-rhG-CSF, 20 μg/kg, single s.c. at 48 h after chemotherapy for each experimental cycle Drug: YPEG-rhG-CSF, 30 μg/kg, single s.c. at 48 h after chemotherapy for each experimental cycle Drug: YPEG-rhG-CSF, 45 μg/kg, single s.c. at 48 h after chemotherapy for each experimental cycle Drug: PEG-rhG-CSF, 100 μg/kg, single s.c. at 48 h after chemotherapy for each experimental cycle |
Completed | Phase 2 | NCT02005458 | |
| Polymeric-PEG | Drug: ADI-PEG 20 | Terminated | Non-squamous NSCLC | Phase 1 | NCT02029690 |
| NPs | Drug: EP0057 Drug: Olaparib |
Recruiting | Lung neoplasms | Phase 1 Phase 2 | NCT02769962 |
| NPs | Drug: BIND-014 | Completed | NSCLC | Phase 2 | NCT01792479 |
| NPs | Drug: BIND-014 (Docetaxel NPs for injectable suspension) | Completed | KRAS-positive patients with NSCLC Squamous cell NSCLC |
Phase 2 | NCT02283320 |
| NPs | Drug: AGuIX Radiation: Radiotherapy |
Recruiting | NSCLC | Phase 1, Phase 2 | NCT04789486 |
| Micelles | Drug: PTX (Genexol) Drug: PTX-loaded polymeric micelle (Genexol-PM) |
Completed | NSCLC | Phase 2 | NCT01023347 |
| Micelles | Drug: PTX micelles for injection Drug: PTX injection Drug: CIS |
Active, not recruiting | NSCLC | Phase 3 | NCT02667743 |
| Albumin | Drug: Nanoparticle albumin-bound PTX/carboplatin | Unknown | NSCLC | Phase 2 | NCT01872403 |
| Albumin | Drug: Carboplatin Drug: Erlotinib hydrochloride Drug: PTX albumin-stabilized nanoparticle formulation Radiation: Radiation therapy |
Completed | LC | Phase 2 | NCT00553462 |
| Albumin | Drug: HLX10 Drug: Carboplatin and nab paclitaxel Drug: Placebo |
Recruiting | NSCLC | Phase 3 | NCT04033354 |
| Albumin | Drug: Nanoparticle albumin-bound PTX | Unknown | NSCLC | Phase 2 | NCT02016209 |
| Albumin | Drug: Albumin paclitaxel Drug: Simvastatin |
Recruiting | SCLC | Phase 2 | NCT04698941 |
| Albumin | Drug: PTX/Albumin-bound PTX Drug: IBI308 |
Recruiting | SCLC | Phase 2 | NCT04056949 |
| Radioactive 18F-Fluoropaclitaxel (FPAC) | Drug: FPAC | Terminated | LC | Phase 1 | NCT01086696 |
| NPs | Drug: TargomiRs | Completed | NSCLC | Phase 1 | NCT02369198 |
* Source: https://clinicaltrials.gov/.